

## The use of joint models for longitudinal and time-to-event data: an application on kidney transplantation

Marie-Cécile Fournier

EA4275 methodS for Patients-centered outcomes and HEalth ResEarch,  
ITUN INSERM UMR1064, Nantes university

August, 25<sup>th</sup> 2016

- 1 To present an application of shared random effect multivariable joint model in renal transplantation

Eur J Epidemiol  
DOI 10.1007/s10654-016-0121-2



CLINICAL EPIDEMIOLOGY

**A joint model for longitudinal and time-to-event data to better assess the specific role of donor and recipient factors on long-term kidney transplantation outcomes**

Marie-Cécile Fournier<sup>1,2</sup> · Yohann Foucher<sup>1</sup> · Paul Blanche<sup>3</sup> · Fanny Buron<sup>4</sup> ·  
Magali Giral<sup>2,5</sup> · Etienne Dantan<sup>1</sup>

- 2 To discuss the usefulness and limits of such complex models in clinical applications

Introduction

Materials

Methods

Results

Discussion

In chronic diseases:

- **Longitudinal markers** allow to follow patient evolution  
→ helpful to determine the most beneficial care
- Occurrence of **events** is overseen

In chronic diseases:


- **Longitudinal markers** allow to follow patient evolution  
→ helpful to determine the most beneficial care
- Occurrence of **events** is overseen

In renal transplantation:


- **Serum creatinine (SCr)** is routinely measured during the follow-up
- 2 major events:
  - ☞ graft loss (return to dialysis or retransplantation)
  - ☞ death with a functioning graft
- **Graft failure** is a major clinical event of interest

It is well-known that:

↗ SCr is associated with ↗ graft failure risk



👉 **Specific role of factors ?**




Introduction

Materials

Methods

Results

Discussion




Introduction

Materials

Methods

Results

Discussion



Introduction

Materials

Methods

Results

Discussion




Introduction


Materials

Methods

Results

Discussion





👉 **Joint model for longitudinal and time-to-event data**  
*(Rizopoulos, Chapman & Hall 2012)*


## The DIVAT cohort ([www.divat.fr](http://www.divat.fr)):

= Données Informatisées et VALidées en TTransplantation

⇒ computerized and validated data in transplantation

French observational and prospective cohort

- 2749 Kidney recipients
- Transplanted between 2000 and 2014
- SCr measurements: yearly recorded
  - 4 SCr measurements / patient were recorded in median
- Event: Graft failure
  - 481 events observed
  - Median follow-up time: 4 years



Distribution of patients included in the DIVAT cohort according to their home town in 2010

Submodel hypotheses are checked separately:

- **Longitudinal process:**

- logarithmic transformation of SCr values
- ⇒ for the linearity and homoscedasticity of the residuals
- 2 random effects included (baseline value and slope)
- unstructured variance-covariance matrix

- **Survival process:**

- no variable with time-dependent effect
- categorization of some continuous variables

Quantitative variables are standardized (as recommended in *Rizopoulos 2012*)

- **Modeling strategy:**
  - ① Specification is defined in a crude joint model:
    - baseline risk function type (Weibull)
    - dependence type (level and slope)
  - ② Covariate selection:
    - univariable analyses (3 fixed effects/variable: on baseline log(SCr), on log(SCr) slope & on graft failure risk)
    - non significant effect removed in backward way (5%)
    - multivariable joint model: stepwise inclusion of significant variables
- **R software (3.0.1 version) with the JM package (1.3 version)** (*Rizopoulos 2010*)


# Multivariable joint model

(n=2584 patients)

Introduction  
Materials  
Methods  
Results  
Discussion

	Longitudinal process				Survival process	
	RC in baseline		RC in slope		HR	p-value
	1-yr SCr	p-value	5-yr SCr	p-value		
Current value of SCr ( $\mu\text{mol/L}$ ), for 25% growth					1.92	<0.0001
Current slope of log(SCr), for 25% growth					1.89	0.0097
Recipient age (for a 10 years increase)	-2.0%	<0.0001	-5.6%	<0.0001	1.35	<0.0001
Recipient gender (male vs female)	7.7%	<0.0001	4.0%	0.0392		
Diabetes histories (yes vs no)	0.0%	0.9866	14.5%	<0.0001		
Cardiovascular histories (yes vs no)	0.0%	0.9812	4.1%	0.0371	1.39	0.0011
3-month SCr (for a 50 $\mu\text{mol/L}$ increase)	8.1%	<0.0001	8.1%	<0.0001	0.84	0.0062
6-month SCr (for a 50 $\mu\text{mol/L}$ increase)	18.0%	<0.0001	18.0%	<0.0001		
Acute rejection episode in 1 <sup>st</sup> year (yes vs no)	5.7%	<0.0001			1.46	0.0010
Anticlass I immunization (+ vs -)	0.0%	0.2707	6.7%	0.0036	1.50	0.0006
Rank of graft: second vs first					1.32	0.0381
Donor type (ref: living donor)		0.0773		0.0022		
Cerebrovascular death	2.8		12.5%			
Non cerebrovascular death	1.9		7.1%			
Donor gender (male vs female)					0.83	0.0589
Donor age (for a 10 years increase)	5.8%	<0.0001	5.8%	<0.0001		

RC: Relative Change; SCr: Serum Creatinine



- Joint models are interested
  - allow to account for the dynamic evolution of the SCr and the informative censoring process...
  - well for endogenous variable
  - for their epidemiological view of chronic disease evolution

but they are limited:

- time-consuming ++
- with several step ( $h_0$ , dependance)
- surprisingly, not really different than mixed model + time-dependent cox model in our application

How can we do to improve their use in clinical trials ?

Thank you for your attention